Avidin is presenting a poster in collaboration with Sanders-Brown Center on Aging, University of Kentucky at the AD/PDTM 2017 meeting, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders on Thursday, March 30, 2017.
Poster: Presentation number: 138
Christopher M. Norris, Susan D. Kraner, Melanie M. Pleiss, Pradoldej Sompol, Irina A. Artiushin, Orsolya Huzian, Laszlo G. Puskas
Presentation number: 138
Our collaborator, Prof. Christopher Norris is focusing on the role of Ca2+ signaling mechanisms in brain aging and neurodegenerative disease, with recent emphasis on the Ca2+/calmodulin dependent protein phosphatase, calcineurin, and its downstream targets.
Q134R, a small molecule, recently developed by Avidin and Soneas Ltd., has successfully finished Phase I clinical trials, appears to inhibit NFAT signaling, without inhibiting CN activity per se. Studies are underway to validate mechanisms of action for Q134 in different neural cell types and to investigate efficacy in mouse models of AD.